- Novel product provides qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter, to unblock occluded inlet holes or open a relief membrane to restore or ...

Approval creates a dedicated reporting code for left ventricular restoration by plication Code 1132T approval marks a ...

The FDA's Circulatory System Devices panel voted 9-2 on Wednesday to recommend approval of the HeartWare Ventricular Assist System as a bridge to heart transplantation for patients with end-stage ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ...

Every once in a while, a breakthrough doesn't just advance medicine—it changes the conversation entirely. SUNNYVALE, Calif., April 17, 2025 /PRNewswire/ -- EBR Systems, Inc. (ASX: EBR) has received ...

SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ -- Anuncia Medical Inc. ("Anuncia" or the "Company"), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF ...

A critical review finds that immunohistochemical injury timelines established in ventricular muscle cannot yet be reliably ...

LAGUNA HILLS, Calif., May 21, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

Six-month outcomes from the Ventricular Catheter Ablation Study, the first-in-human evaluation of its FieldForce Ablation System for ventricular tachycardia (VT), have been published in Circulation.